Table 1.
IC50 values of known potent UGTs inhibitors and AS, βC, CA, LU and ZE towards the seven UGTs isoforms.
| UGTs | IC50 Values (μM) | ||||||
|---|---|---|---|---|---|---|---|
| Known Potent Inhibitors | AS | βC | CA | LU | ZE | ||
| UGT1A1 | Nilotinib | 1.55 ± 0.118 | >50 1 | 18.8 ± 2.07 | 38.5 ± 4.65 | 45.5 ± 4.01 | >50 |
| UGT1A3 | Deoxyschizandrin | 5.17 ± 0.700 | >50 | 28.3 ± 4.40 | 41.2 ± 3.14 | >50 | >50 |
| UGT1A4 | Hecogenin | 8.07 ± 2.60 | >50 | 34.9 ± 5.98 | >50 | 28.7 ± 3.79 | >50 |
| UGT1A6 | Diclofenac | 106 ± 26.6 | >50 | >50 | >50 | >50 | >50 |
| UGT1A9 | Niflumic acid | 0.390 ± 0.0256 | >50 | >50 | >50 | >50 | >50 |
| UGT2B7 | Efavirenz | 37.8 ± 2.37 | >50 | >50 | >50 | >50 | >50 |
| UGT2B15 2 | Amitriptyline | 69.4 ± 10.6 | >50 | >50 | >50 | >50 | >50 |
IC50, 50% inhibitory concentration; AS, astaxanthin; βC, β-cryptoxanthin; CA, canthaxanthin; LU, lutein; ZE, zeaxanthin. 1 The residual activities at the highest tested xanthophylls concentration (50 μM) were greater than 50%. 2 Recombinant UGT2B15 supersomes was used. Data represent the mean ± standard deviation of triplicate determinations.